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Abstract
In case of accidental release of radionuclides in a nuclear facility or in the environment, internal contamination (inhalation, in-
gestion or wound) with actinides represents a severe health risk to human beings. It is therefore important to provide effective che-
lation therapy or decorporation to reduce acute radiation damage, chemical toxicity, and late radiation effects.
Speciation governs bioavailability and toxicity of elements and it is a prerequisite tool for the design and success of new ligands
or chelating agents. The purpose of this review is to present the state-of-the-art of actinide decorporation within biological media, to
recall briefly actinide metabolism, to list the basic constraints of actinideeligand for development, to describe main tools developed
and used for decorporation studies, to review mainly the chelating agents tested for actinides, and finally to conclude on the future
trends in this field. To cite this article: E´. Ansoborlo et al., C. R. Chimie X 33 (2007).
 2007 Acade´mie des sciences. Published by Elsevier Masson SAS. All rights reserved.
Re´sume´
En cas de rejet accidentel de radionucle´ides dans une installation nucle´aire ou dans l’environnement, il existe un risque de con-
tamination interne (inhalation, ingestion ou blessure) pour l’homme et il est important de pouvoir fournir un traitement the´rapeu-
tique par des agents che´latants ou de´corporation permettant de re´duire la dose, la toxicite´ chimique et les effets retarde´s des
radiations.
La spe´ciation domine la biodisponibilite´ et la toxicite´ des e´le´ments et repre´sente un outil indispensable pour la conception et
l’efficacite´ de nouveaux ligands ou che´latants. Le but de cet article est de pre´senter l’e´tat de l’art sur la de´corporation des actinides
en milieu biologique, de rappeler les grandes lignes du me´tabolisme des actinides, de lister les contraintes indispensables actinidee
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2 E´. Ansoborlo et al. / C. R. Chimie xx (2007) 1e10ligands pour la de´corporation, de de´crire succinctement les principaux outils expe´rimentaux ou analytiques utilise´s, de passer en
revue les principaux ligands teste´s pour les actinides et de pre´senter les orientations du futur dans ce domaine. Pour citer cet article :
E´. Ansoborlo et al., C. R. Chimie X 33 (2007).
 2007 Acade´mie des sciences. Published by Elsevier Masson SAS. All rights reserved.
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In case of accidental release of actinides (An: Th, U,
Np, Pu, Am, Cm) in a nuclear facility or in the environ-
ment, internal contamination by either acute or chronic
exposure has the potential to induce both radiological
and chemical toxicities. Contrary to some heavy metals,
actinides have no known essential role in the normal
biochemical reactions occurring in living organisms, in-
cluding plants, animals, and humans. Whatever the con-
tamination route (inhalation, ingestion or wound), the
radionuclide is absorbed, and then transported by blood
(the absorption rate depends on the dissolution proper-
ties of the initial physico-chemical form) prior to depo-
sition in the target organs (e.g. bone, kidney, and liver) in
which it is stored and then slowly and partially excreted
in the urine and faeces. These biological steps are dom-
inated by kinetics and controlled by the thermodynamic
equilibria of the radionuclide with biological ligands,
highlighting the important role of speciation [1]. Acti-
nides, like many exogenous metals, link with different
biological ligands (proteins, amino acids, etc.) and
might take the place of essential elements by analogy,
but these phenomena are not always well known. Bioki-
netic models for actinides are rather well known and are
described in detail in various publications of the Interna-
tional Commission on Radiological Protection (ICRP)
[2e4] and the National Council on Radiation Protection
and Measurements (NCRP) [5]. Nevertheless, those bio-
kinetic models are more or less phenomenological and it
would be of great importance to have a more detailed
molecular understanding of them.
Consequently, the interactions of actinides with the
various constituents of cells and tissues are important
not only for a better understanding of the mechanisms
controlling their specific tissue deposition pattern and
the initiation of toxic effects, but also for the develop-
ment of effective methods for treating persons who
may become contaminated. In case of internal human
actinide contamination, it is important to provide effec-
tive chelation therapy to reduce acute radiation damage,
chemical toxicity, and late radiation effects.Please cite this article in press as: E´. Ansoborlo et al., C. R. Chim. (200Speciation analysis is thus a prerequisite tool, neces-
sary for addressing the behaviour of cationic and anionic
species within biological media, in order to understand
better absorption and transport mechanisms in living
organisms, distribution in organs or cells, and conse-
quently bioavailability and toxicity. It may also yield
significant input to decorporation [6] studies or treat-
ment of the contamination, by providing guidance on
the structure, affinity and design of potential specific
chelating agents synthesized and used for the elimina-
tion of an incorporated radionuclide.
This review is aimed at presenting: (i) the state of the
art of decorporation studies; (ii) an outline on actinide
metabolism, as known from the available experimental
in vivo data; (iii) a review of the constraints for actinide
decorporation, including some fundamental aspects of
actinide solution chemistry, such as valence states, redox
potentials, hydrolysis and complexation properties; (iv)
what are the main tools developed and used for decorpo-
ration studies; (v) a brief summary on existing chelating
agents and what is known and missing about chelation of
actinides with relevant biological molecules, including
the problem with the interference and the balance of es-
sential trace elements when using chelation therapy; and
finally (vi) what are the future trends in this field.
2. State-of-the-art of decorporation treatments
The potential hazards to human health of the nuclear
materials, including actinides, activation and fission
products, were recognized early, stimulating the search
for effective ways to remove internally deposited radio-
elements from the body. Two major synthetic reviews,
presented as guidebooks for decorporation of radio-
nuclides from the human body have been published
[7,8]. The main goal was to decrease the whole body
content or a specific organ content in order to decrease
the effective dose and so avoid deterministic and/or sto-
chastic effects [6]. Nevertheless, the proposed or devel-
oped treatments should mainly vary as a function of the
intake pathway throughout the organism, the level of
contamination (mass and activity), the chemical and7), doi:10.1016/j.crci.2007.01.015
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intervention time after the incident.
Table 1 reviews the different main treatments that
have been developed and applied to decorporation tak-
ing into account the specific intake pathways and
physico-chemical states of the actinides: (1) for con-
tamination by inhalation, which is mainly concerned
by aerosols that display different chemical solubilities,
the proposed treatments aimed at increasing the solubil-
ity of the actinides deposited in the human respiratory
tract and the mechanical removal along the respiratory
tract via the gastro-intestinal tract, and finally at allow-
ing a chelation of the absorbed fraction into the blood;
(2) for contamination by ingestion, the developed treat-
ments were mainly gastric dressing, precipitation, purge
and chelation of the absorbed fraction into the blood;
(3) for wound contamination, several treatments have
been applied, including washing, surgical excision
and dressings with additional specific chelating agent
like gels, and chelation of the absorbed fraction into
the blood.
These three different types of intake clearly show
that therapeutic treatments should be adapted to the in-
take pathway, and also underline that, depending on dif-
ferent speciation of the actinides, blood is a common
compartment before distribution in the organism.
3. Actinide metabolism
The biokinetics and bioinorganic chemistry of acti-
nides following inhalation, ingestion and injection
have been well studied in the past 50 years: models
were reviewed and adopted in ICRP Publications 67
and 69 [3,4] and NCRP [5], discussed in Refs. [9e14]
and currently revised by ICRP internal dosimetry
Table 1
Main treatments used in decorporation therapies versus the type of
incorporation












iv, Intravenous; ip, intraperitoneal; im, intramuscular.Please cite this article in press as: E´. Ansoborlo et al., C. R. Chim. (200(INDOS) working group. The main results summarized
in Table 2 clearly show that actinides can be more or
less absorbed into the blood (depending on their speci-
ation) during a short transition time (10 min to 1 h)
before their distribution into target organs. It is also
important to remember that only a small part of the ac-
tinides fixed in these target organs can recirculate in the
blood. All these internal physico-chemical phenomena,
which mainly correspond to absorption, retention (sorp-
tion, desorption) and excretion, are time dependent but
also speciation dependent.
Within biological media, it is also important to note
that plutonium and thorium are considered to be only
present under An(IV) form, americium and curium under
An(III) form, neptunium can be present under both forms
An(IV) and An(V), and uranium under U(VI) form.
3.1. Main actinides’ biological ligands
Most studies on actinide biokinetics focus on blood,
since the overall behaviour of radionuclides is depen-
dent on their residence time in this compartment. Sev-
eral reviews [9e15] showed that most actinides, when
present in blood, are mainly bound to the iron transport
protein transferrin (Tf) [17], although the binding char-
acteristics may vary from element to another. Tf ap-
pears to bind efficiently to Pu(IV), Th(IV) and Np(IV)
(more than 80% of these actinides are complexed with
Tf), whereas U(VI) is only moderately bound to Tf
(w30%) (this actinide is also bounded to haemoglobin
or red blood cells). Am(III) and Np(V) seem also to be
weakly bound (w30%) to Tf. Am(III) is probably asso-
ciated with other proteins (such as albumin) as the Ame
Tf complex is not as stable as that of Pu [13,14,18].
Similar experiments have been performed on protein
binding in tissue/organ deposition sites including liver,
bone, and kidney. Several reviews [13,14,19,20] present
the possible transfer mechanisms of Np(V), Pu(IV) and
Am(III) from blood to liver cells, and describe possible
time- and mass-dependent binding of these actinides in
the liver cells with high molecular weight proteins such
as calmodulin, ferritin and lipofuscin. It has also been
shown [21] that hepatocyte cells concentrate more plu-
tonium than sinusoidal cells and that Kuppfer cells play
an important role in the phagocytosis of polymeric
forms of plutonium.
Investigations concerning bone deposition are rare
but studies [10,13] using mineralized bone or uncalci-
fied matrix models for bone have, however, identified
binding by proteins such as sialoproteins, chondroitin
sulphateeprotein complexes and glycoproteins as well
as by transferrin.7), doi:10.1016/j.crci.2007.01.015
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Biokinetic data on actinides [3,4,9e14]
Actinides Thorium Uranium Neptunium Plutonium Americium, Curium
Chemical form Th(IV) U(VI) Np(IV) Np(V) Pu(IV) Am(III) Cm(III)
Ionic radius (A)a 1.00 2.80 0.95 2.90 0.93 1.00 0.98
Blood stay 10% 1 d 25% 5 min 20% 1 h <1% 1 h <1% 1 d <1% 1 d
0.3% 10 d 1% 1 d <1% 1 d
Blood complexes 100% Tf 50% HCO3
 80% Tf 70% Free 100% Tf 30% Tf
30% Tf 30% Tf
20% Red cells
Organ retention
Bone 70% 10e15% 30e50% 30e50% 50% 30%
Liver 5% e 2e10% 2e10% 30% 50%
Kidneys 3% 12e25% e 1% e e
Soft tissues 4% 5% 5% 5% 10% e
Urinary
excretion
4e6% 5 d 65% 1 d 3e4% 1 h 15e20% 1 h 0.4% 1 d <1% 1 d
7e9% 20 d 70% 6 d 15% 1 d 20e40% 1 d 1.4% 14 d
Ingestion f1
b
Type M 5 104 2 102 5 104 5 104 5 104
Type S 2 104 2 103 1 105
ICRP modelb 69 69 67 67 67
Tf, transferrin.
a Ionic radius: selected values between Goldschmidt, Pauling, Shannon and Marcus radii [16].
b f1 is the fraction of an element entering the gastrointestinal tract which reaches blood [2e4]. Type M and Type S compounds are defined in ICRP
models [2e4] as moderately (M) and slowly (S) absorbed compounds to blood.4. Constraints for actinide decorporation and
some fundamental aspects of actinide
solution chemistry
The earliest efforts to remove actinides by means of
dietary manipulation, supplements of hormones, or by
scavenging through the use of common carboxylic acids
or other complexing agents, or colloidal citrate were
rather discouraging in terms of efficiency.
The methodological approach which was adopted
by the scientific community from 1950 to 2000 was
to develop chemical agents that would complexPlease cite this article in press as: E´. Ansoborlo et al., C. R. Chim. (200selectively actinides directly in the blood (which is
the main pathway either by direct absorption or
through recirculating absorption) and would form ex-
cretable low-molecular-weight chelates. Table 3 sum-
marizes basic specifications [22] between actinides
and potential chelating agents that should reflect
some aspects of the solution chemistry of actinides
and should be essential for clinical use. Some of
these specifications have also been previously given
for iron [23].
The sequestering agents should exhibit certain desir-
able qualities under physiological conditions. HenceTable 3
Basic specifications between actinides and potential chelating agents
Actinides Ligands
Hard cations (Pearson) Donor atoms O>N> S
Oxidation states 3e6 (Am3þ, Np4þ, NpO2
þ, Pu4þ, UO2
2þ) Denticity or number of donor sites
Hydrolysis ability M4þ>MO2
2þ>M3þ>MO2
þ Stereochemistry of ligand, size
Redox (e.g. Np(IV), Np(V)) Stability (H bond)
Numerous complexes (OH, H2PO4
, HCO3
) Selectivity/(Naþ, Ca2þ, etc.)
Dissociation constant kinetics of stable complexes are slow Ionisation at physiological pH
Hydrosoluble
Kinetic and thermodynamic
Ratio of ligand:metal (>1000:1)
Toxicity and FDA
FDA¼ federal drug authorization.7), doi:10.1016/j.crci.2007.01.015
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such as those listed hereafter.
1. The chelating moieties of the ligand should be
sufficiently deprotonated under physiological con-
ditions to ensure efficient scavenging of the actinide
of interest.
2. Ligands can be structurally classified according to
the number of donor atoms (one donor atom corre-
sponds to a monodentate, two to bidentate, and so
on) that is involved in the metal coordination. The
possibility for a polydentate ligand to coordinate
depends both on the coordination geometry of the
metal ion and on the steric constraints in the ligand.
The number of chelate rings formed in the resultant
ligandemetal complex is a factor of great impor-
tance in the stability of the complex: the more the
rings, the greater the stability of the complex, and
formation of complexes with a 1:1 stochiometry
should be recommended. For example, an hexaden-
tate ligand like EDTA can use all six donor atoms
when coordinating An(III) or An(IV), but not in
complexes with actinyl ions An(V) or An(VI).
3. Site(s) of action (e.g. blood, bone, kidney) of the
sequestering agent need to be considered as this af-
fects its physico-chemical properties for targeting.
It has been shown that some actinideeligand com-
plexes could behave differently from the biological
actinide complex: for example, uranium for which
main target organ is kidney can be displaced to
liver as a uraniumecalixarene complex [8].
4. The agent should have high selectivity for actinides
and low affinity for other biologically significant
essential metal ions such as Ca(II), Na(I), K(I),
Fe(II), and Zn(II). A good way to avoid such inter-
ferences is to use the ligand (e.g. DTPA) under dif-
ferent chemical forms such as Na3CaDTPA or
Na3ZnDTPA [8].
5. Ligands of low toxicity are required: it has been ob-
served that with the same basic chelating units, low-
denticity ligands were generally less toxic than
those of high denticity, and linear ligands were
less toxic than branched or cyclic ligands [23]. Nev-
ertheless, there are some exceptions, like octaden-
tate LIHOPO [18].
6. The bioavailability of the sequestering agent should
be considered as should excretion pathways of the
actinide-sequestering agent complex once it is
formed in vivo; it is important to ensure that the
agent is not metabolically degraded to metabolites
and then unable to bind the metal. Ideally for max-
imal chelation, a chelator must be present withinPlease cite this article in press as: E´. Ansoborlo et al., C. R. Chim. (200the extracellular fluids at both reasonable concentra-
tion (10e25 mM) and duration to ensure interception
of the actinide from either the intracellular or the
extracellular pool.
7. The importance and desirability of lipophilic prop-
erties should be addressed.
8. High oral efficiency is very desirable for practical
application and molecular mass is a critical factor
which influences the rate of oral drug absorption:
a ‘‘cut-off’’ molecular mass between 300 and
500 Da for absorption by the human small intestine
has been noticed [23].
9. Finally, for contamination incidents, the sequester-
ing agent should have a federal drug authorization
(FDA) and should be readily available at a low cost
and very quickly.
On the other hand, the solution chemistry of acti-
nides exhibits certain properties under physiological
conditions such as those listed below.
1. Actinides are ‘‘hard’’ cations with a large ionic po-
tential (charge-to-ionic-radius ratio: z/r) and there-
fore prefer ‘‘hard’’ oxygen and negatively charged
oxygen donors. The bonding between cation and
ligand is relatively well described by an electrostatic/
ionic model, where covalency is playing a minor
role. Overall, they show a stronger preference for ox-
ygen donor atoms and so interact preferentially with
ligands containing such groups, rather than nitrogen,
sulphur or phosphorous donors. Their ability to form





the same oxidation state, it is well known that the rel-
ative stability of the complexes with hard acids
increases with the atomic number, due to the con-
traction of the actinide ionic radii.
2. The light actinide series (from Th to Cm) corre-
sponds to the filling of the 5f and 6d electron shells
and exhibits a range of oxidation states in aqueous
media from þIII to þVI [24e26]. The most stable
redox states in acidic aqueous solution are þIV for
plutonium and thorium, þVI for uranium, þIV and
þV for neptunium, and þIII for americium and
curium [25,26].
3. Actinide ions underþIII andþIV forms have a coor-
dination number of 8e12, whereas An(V) and An(VI)
have a coordination number of 6e8 in the equatorial
plane, and therefore have a tendency to form stable
complexes with ligands of higher denticity.
4. Generally, for discussion of kinetic effects, the re-
dox reactions of actinide species have been divided7), doi:10.1016/j.crci.2007.01.015
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tron transfer (M4þ/M3þ and MO2
2þ/MO2
þ pairs),
for which reactions of simple electron exchange
are fast, and those also requiring formation and/
or rupture of metal/oxygen bonds (e.g. M4þ/
MO2
þ pairs), which tend to be kinetically slow.
5. A noteworthy aspect of actinide solution chemistry
is the importance of hydrolysis reactions [25,26],
which may be significant even in acidic media,
such as:
Mnþ þ mH2O4MðOHÞðnmÞþm þ mHþ
The strength of hydrolysis follows the order
M4þ>MO2
2þ>M3þ>MO2
þ. The M4þ and MO2
2þ
species are reported also to form very stable hydroxide
oligomers (i.e. [M(OH)i]n), depending on the actinide
concentration. It is also important to mention that the
transformation from hydroxide to hydrated oxide is
non-reversible.
5. Review of main tools developed and
used for decorporation studies
There are several analytical, experimental or model-
ling tools which can be used to perform decorporation
studies and to test the efficiency of ligands toward acti-
nide decorporation.
The first tool is the rational design and synthesis of
ligands based on specification actinideeligand, as de-
scribed in Table 3. The most illustrative example con-
cerns the similarities observed in the 1980s [27]
between Fe(III) and actinides, especially Pu(IV), about
their chemical and biological transport as well as their
distribution properties [18,27]: they include ionic po-
tential (z/r) for Fe(III) and Pu(IV) (4.6 and 4.3, respec-
tively), formation of highly insoluble hydroxides
(M(OH)n) and similar first-hydrolysis constants
(Pu(OH)3þ and Fe(OH)2þ). This analogy allowed the
development of all the compounds based on sidero-
phore chemistry. A second example is the great chem-
ical affinity between uranyl ion and phosphates and the
current use of 1-hydroxyethane-1,10-diphosphonic acid
(HEDP) (a simple phosphonate compound with the fed-
eral drug authorization (FDA)) in the medical treatment
of bone disease: this association led several laboratories
to develop and synthesize numerous promising poly-
phosphonate compounds [28e31]. The interaction be-
tween an actinide and a decorporating agent or a biolog-
ical molecule can be determined typically by the use of
analytical and speciation tools [14,32], but also by thePlease cite this article in press as: E´. Ansoborlo et al., C. R. Chim. (200use of in vitro screening tests based on a displacement
method with a reference chelating agent such as sulfo-
chlorophenol [28,33]. These tools are very useful and
allow one to test and select numerous compounds for
their actinide-binding capabilities, before performing
any in vivo experiments. In complement to this ap-
proach, molecular dynamics (MD) has also been devel-
oped in the last decades and successfully applied to
determine structures and energy properties of biologi-
cal macromolecules and proteins [14]. This in silico
simulation approach can be used either at the design
step or after in vitro or in vivo experiments. More recent
studies have also highlighted the possibilities of using
quantum chemistry calculations to investigate chemical
reactions (bond breaks or formations), taking into
account clusters (around 100 atoms) of these large mo-
lecular systems [35e39].
The second tool is the in vivo experiments on animals,
which have been largely used and very well described
in several recent reviews [8,13,34]. A recent report
[40] made by a French collective working group and
mobilized by the occupational medicine department
presents a review of Ca-DTPA injections used for
medical treatment of Pu and Am worker contamina-
tion in the CEA and COGEMA plants from 1970 to
2003. This report reviews data concerning 1158 injec-
tions administered to 469 persons and proposes posol-
ogies and therapeutic schemes following these
observations on humans.
6. Review of chelating agents developed and what
is known and missing about chelation of actinides
with relevant biological molecules
This first approach has resulted in much research for
new ligands [13,18,28e31] with higher affinity and se-
lectivity for actinides and/or better lipophilicity to pen-
etrate biomembranes.
Exhaustive reviews have recently been performed
[8,13,14,18,34] on the development of improved
actinideesequestering agents using lanthanide metal
ions as suitable models as well as natural iron-chelating
agents as a source of inspiration.
Among the different families of ligands synthesized,
the main families of organic compounds that have been
synthesized and tested for their in vivo decorporating ef-
ficiency on actinides since 50 years, are given in Table 4.
They comprise:
(i) polyaminocarboxylic acids such as diethylenetria-
minopentaacetic acid (DTPA) which is a reference7), doi:10.1016/j.crci.2007.01.015
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Main families of ligands efficient in terms of decorporation for actinides
Ligand family Example of ligands Elements
Polyaminopolycarboxylics (Ca,Zn,Na) DTPA Pu(IV), Am(III)
Siderophores LICAM (catechol) Pu(IV), Am(III)
(Basis: enterobactin) LIHOPO (pyridinone)a Cm(III), Th(IV), U(VI)
Macrocycles Calixarens (toxic) U(VI)
Crown ether
Bisphosphonics HEDPa U(VI), Np(IV)
Polyaminopolyphosphonates CDTPa U(VI)
Polyphosphonates tris-Bisphosphoniqesa U(VI)
Various Bicarbonates, Tiron U(VI)
a Presented in Figs. 1 and 2.ligand in decorporation and shown to be effective
for plutonium and americium [8,13,18,34];
(ii) natural siderophores such as ferrichrom, desfer-
rioxamine (DFOM), and enterobactin (EB); multi-
dentate catecholate and hydroxypiridonate ligands
based on the EB model were then synthesized con-
taining subunits such as catechol (CAM), sulfoca-
techol (CAM[S]), carboxycatechol (CAM[C]),
catecholamide (TAM), and 1,2-hydroxypiridinone
(1,2-HOPO) attached through amide linkage to lin-
ear (LI), cyclic (CY), aromatic (ME), or branched
(TREN, H(2,2)) backbones that were tested in
vivo and found to be mainly effective for uranium,
plutonium, americium, curium and thorium [8,13,
18,34]. Among these numerous compounds synthe-
sized and tested, the two most famous are certainly
3,4,3-LI(1,2-HOPO) and 5-LIO(Me-3,2-HOPO)
(Fig. 1);
(iii) macrocyclic compounds including cryptates, cali-
xarenes and crown ether families that were poten-
tially promising ligands but were found to be
toxic [8,34];
(iv) poly-phosphonates with the simplest basic com-
pound, 1-hydroxyethane-1,10-diphosphonic acidPlease cite this article in press as: E´. Ansoborlo et al., C. R. Chim. (200(HEDP), found to be effective for uranium and
neptunium, and also a large variety of other phos-
phonates under dipode or tripode forms that were
found to tightly bind uranyl ion [8,28e31,34]
(Fig. 2);
(v) various other compounds that were not really ef-
fective, such as bicarbonate and 1,2-dihydroxy-
3,5-benzenedisulfonic acid (Tiron), and alginate
[8, 34].
In parallel, the determination of thermodynamic
equilibrium constants provides a quantitative measure-
ment of the affinity of a particular ligand for actinide
ions [13,14]. Some selected stability constants of acti-
nides with selected ligands, such as DFOM, DTPA,
EDTA, are given as examples in Table 5 and compared
with some selected potential biological ligands. It is im-
portant to point out that these equilibrium constants refer
to laboratory systems where the experimental conditions
are such that only binary complexes are formed. In vivo,
there are more potential ligands and one must not disre-
gard the possible formation of ternary complexes. As the
pH is sufficiently high, there may also be ternary Ane































Fig. 1. Examples of two efficient hydroxopyridonate compounds.7), doi:10.1016/j.crci.2007.01.015
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Fig. 2. Examples of powerful ligands for uranium (UO2
2þ) or lanthanides [28e31].7. The future trends of decorporation
A second approach of decorporation, which is rather
a pharmaceutical approach mainly developed with
DTPA for plutonium, started from the experimental ob-
servation that the access to Pu by DTPAwithin the organ
site was limited, due to the difficulty for DTPA to cross
biological membranes. Liposomes, which are multi-
lamellar vesicles and which can be encapsulated with
a ligand such as DTPA, were extensively studied and
evaluated in the 1970s, but came to an end after the
late 1980s, despite promising results in animal studies.
This pharmaceutical approach, also called vectorisation,
is simpler since the main goals are to modify the pharma-
cokinetic disposition of DTPA in order to fit with the Pu
traffic in vivo and to better penetrate biomembranes. As
much progress has been made in liposome technology
during the past two decades, this strategy was intensively
revisited [56e58], and optimization of formulations led
to polyethylene glycol-coated stealth liposomes around
100 nm decreasing the retention of Pu in the liver after
7 days by a factor 30 and increasing the excretion inPlease cite this article in press as: E´. Ansoborlo et al., C. R. Chim. (200the urine by a factor 10 compared to animals with no
treatment.
This new approach clearly shows that decorporation
can be achieved more efficiently by using optimized li-
posomal formulation of a ligand (e.g. DTPA) than by
the usual free ligand treatment.
Future trends of decorporation should take into ac-
count basic specifications between actinides and ligands
as summarized in Table 3. The design and synthesis of
new higher performance ligands should still be encour-
aged but not considered only as a quest for the ‘‘Holy
Grail’’ and should mainly focus on their formulation,
which is essential for better access to the actinides as
well as to any other metal in different biological com-
partments. An important issue that is often neglected
due to the lack of information, and that should be seri-
ously considered in the future is the role of the redox
state within biological media (mainly enzymatic reac-
tions), which is strongly related to oxygen and its free
radicals (stress reactions) and iron chemistry. Thus the
competition between Fe(III) and An(III) and An(IV)
should certainly be the best illustration to explore. It isTable 5
Stability constants of some biological and chemically relevant actinide complexes
Actinides Thorium Uranium Neptunium Plutonium Americium Curium
Chemical form Th(IV) U(VI) Np(IV) Np(V) Pu(IV) Am(III) Cm(III)
log K1 (I¼ 0)
Glycine (L) 10.5b 8.0b 3.3b (I¼ 0.1) 4.1b (I¼ 1)
Cysteine (L2) 9.2b 6.7b 4.2b (I¼ 1)
Aspartate (L2) 11.0b 9.3b 2.6b (I¼ 1) 6.1b
Glutamate (L2) 10.8b 9.2b 2.7b (I¼ 1) 5.6b (I¼ 1)
Lactate (L) 5.7b 2.9b 2.1b 2.1b 2.4b (I¼ 1)
Citrate (L3) 13.7a 9.0a 16.3 [48] 3.7a 15.3a (I¼ 0.5) 8.6a
Transferrin 20.4c 16 [51] 24.7c [52] 2.1c 22.5 [49,50] 10.4c 10.6c
Desferrioxamine L3 21.5b 30.8b
Tiron (L4) 21.1b 17.5b
NTA (L3) 19.5b 10.8b 17.3b (I¼ 1) 7.5b 13.9b
EDTA (L4) 26.6b 13.7a 31.2a 9.3a 26.4 [53] 19.7a
DTPA (L5) 33.1b 11.0b 29.3b (I¼ 0.5) 11.7b 29.5b (I¼ 0.5) 26.2b
a Data from NEA, OECD, PSI [41e47].
b IUPAC database 2004 [54].
c Estimated by analogy [14]. Ionic strength correction (I) was done when necessary using Davies’ equation. Some constants are given with I 0.5
which are indicative values whereas they cannot be used for calculation.7), doi:10.1016/j.crci.2007.01.015
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in some cases (e.g. An(III)) result in competition with the
intracellular or extracellular balance, calcium balance
(Ca(II) has a very similar ionic radius as An(III) ions).
Finally, it is important to mention that in France, the
‘‘Commissariat a` l’ e´nergie atomique’’ (CEA), in associ-
ation with three other French scientific research insti-
tutes, namely the ‘‘Centre national de la recherche
scientifique’’ (CNRS), the ‘‘Institut national de la re-
cherche agronomique’’ (INRA), and the ‘‘Institut na-
tional de la sante´ et de la recherche´ me´dicale’’
(INSERM), and supported by the ‘‘Ministe`re de´le´gue´ a`
l’Enseignement et a` la Recherche’’, initiated a pro-
gramme of interdisciplinary research in 2004 called
‘‘Nuclear and Environmental Toxicology’’ (ToxNuc-E).
Among the 15 projects treated in this programme, there
are three projects that focus on actinides: one on decor-
poration, one on molecular targets, and one on biological
chelation.
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